How Ozempic is Prescribed for Weight Loss: An In-Depth Guide

Last reviewed: June 21, 2026

Last updated: June 21, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for type 2 diabetes that now serves as a powerful weight loss medication. Clinical trials show that patients using semaglutide lose an average of 15% of their body weight over 68 weeks when combined with lifestyle changes. PlexusDx delivers compounded semaglutide injections from licensed 503A pharmacies across all 50 states, with flexible pricing that doesn't increase as your dose adjusts.

What Semaglutide Is and How It Works in Your Body

Semaglutide mimics a hormone your gut naturally produces called GLP-1, which signals your brain that you're full and satisfied. When you take semaglutide, it activates GLP-1 receptors in areas of your brain responsible for appetite control, reducing hunger signals and food cravings. The medication also slows how quickly food leaves your stomach, helping you feel fuller longer after meals. Beyond weight loss, semaglutide improves blood sugar control and may reduce cardiovascular risk in people with obesity.

The drug was first approved by the FDA in 2005 as Byetta for diabetes management, then reformulated as a once-weekly injection called Ozempic in 2017. Pharmaceutical companies began noting dramatic weight loss in diabetic patients and launched Wegovy, the semaglutide formulation specifically indicated for chronic weight management in 2021. Today, semaglutide represents one of the most studied weight loss therapies, with decades of safety data supporting its use in both diabetic and non-diabetic populations.

Semaglutide Dosing Schedules and Titration Protocols

Most semaglutide weight loss programs follow a gradual titration schedule, starting at a low dose and increasing every 4 weeks until reaching an effective maintenance dose. A typical protocol begins at 0.25 mg once weekly, increasing to 0.5 mg in week 5, then advancing by 0.25 mg increments every 4 weeks—commonly reaching 1.0 to 2.4 mg weekly. PlexusDx determines your starting dose and titration schedule based on your health history, current medications, and metabolic profile, ensuring steady progress without unnecessary side effects. Your dose may need to increase as your body responds and adapts, but your monthly price remains the same regardless of dose level.

The titration approach serves two purposes: it allows your body to adjust to the medication's effects gradually, minimizing nausea and gastrointestinal symptoms, and it identifies the lowest effective dose for your individual physiology. Some patients achieve meaningful weight loss at 0.5 mg weekly, while others require 1.7 mg or higher for optimal results. Weekly injections are administered subcutaneously—typically in the abdomen, thigh, or upper arm—and can be self-administered at home after initial instruction from your healthcare provider.

Weight Loss Results and Timeline: What Research Shows

The landmark STEP trials, which enrolled nearly 4,600 adults with obesity, demonstrated that participants on semaglutide lost an average of 15% of baseline body weight by week 68, compared to just 2.4% in the placebo group. Patients using the highest doses (2.4 mg weekly) achieved even greater results, with average weight loss exceeding 17% of body weight. Weight loss typically begins within the first 2 to 4 weeks of treatment, with the most dramatic changes occurring between months 3 and 6. Results continue to improve through month 12, after which weight generally stabilizes at a new, lower baseline.

Individual outcomes vary significantly based on genetics, lifestyle adherence, starting weight, and metabolic factors. Some patients lose 20% to 30% of their body weight, while others experience more modest but still clinically meaningful losses of 8% to 15%. Importantly, research shows that weight loss is not permanent if treatment stops—most patients regain lost weight within 6 to 12 months after discontinuing semaglutide. This underscores why weight loss medications like semaglutide function best as part of a long-term weight management strategy rather than a temporary intervention.

Semaglutide Side Effects, Safety Monitoring, and When to Seek Help

Nausea is the most commonly reported side effect, affecting up to 30% of patients on semaglutide, though it typically decreases after the first few weeks as your body adapts. Other gastrointestinal effects include vomiting, constipation, and diarrhea, particularly during dose increases. Headache and fatigue occur in 10% to 15% of users, usually mild and transient. Serious side effects are rare but may include pancreatitis (pancreas inflammation), gallbladder disease, and thyroid concerns; inform PlexusDx immediately if you experience severe abdominal pain, persistent vomiting, rapid heart rate, or neck swelling.

PlexusDx requires baseline metabolic screening and periodic check-ins to monitor your response, side effect profile, and overall health markers. You should not use semaglutide if you have a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, as animal studies have shown an association with thyroid C-cell tumors. Pregnant individuals must discontinue semaglutide at least 2 months before attempting conception. Regular communication with the PlexusDx clinical team helps identify and manage any concerns early, ensuring safe and effective treatment throughout your weight loss journey.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Is compounded semaglutide the same as brand-name Ozempic or Wegovy?

Compounded semaglutide contains the same active pharmaceutical ingredient as Ozempic and Wegovy but is manufactured by licensed 503A compounding pharmacies rather than large pharmaceutical companies. PlexusDx sources from accredited compounders that follow strict quality and sterility standards. Compounded versions cost significantly less—at $189/mo month-to-month, or from $149/mo on the 6-month plan—while delivering equivalent clinical results when dosed properly.

How much weight will I lose on semaglutide?

No — the Precision Peptide Genetic Test does not predict your response to semaglutide or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

What does semaglutide cost with PlexusDx?

PlexusDx semaglutide injections are $189/mo month-to-month, or from $149/mo on the 6-month plan across all commitment tiers with flat pricing — your dose may go up, but your price won't. The medication is HSA/FSA eligible, requires no insurance, and has no membership fees. Serve all 50 states with home delivery from licensed 503A compounding pharmacies.

Is semaglutide safe for long-term use?

Semaglutide has decades of safety data from diabetes treatment and multiple large clinical trials specifically for weight loss. Most side effects are mild and improve within weeks. Serious complications are rare when used under medical supervision. PlexusDx provides ongoing monitoring to catch any concerns early and ensures you're a good candidate before starting treatment.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

Yes—the PlexusDx Precision Peptide Genetic Test analyzes 14 metabolic pathways and 49 peptides, including key GLP-1 pathway variants like GIPR rs1800437 that influence your response to semaglutide. This $298 test, taken after your first month of treatment, provides personalized insights to help optimize your dose and therapy approach based on your unique genetic profile.

Related Reading

• Ozempic For Weight Loss 2
• Average Weight Loss On Ozempic
• Weight Loss Drugs Like Ozempic
• Ozempic Weight Loss Before And After Pictures

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.